Supplementary Figure S4 from T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma

Key Points

• Main finding indicates RAS(ON) inhibition affects PDAC tumor responses by modifying the immune landscape.
• The study suggests that early immune changes correlate with T-cell activity in pancreatic tumor models.
• Inhibition of RAS(ON) leads to notable shifts in the PDAC microenvironment, impacting tumor behavior.
• Understanding these immune dynamics could enhance therapeutic strategies for pancreatic cancer.

Abstract